Johnson & Johnson's seltorexant improves depressive symptoms and sleep disturbances in major depressive disorder patients in a late-stage trial.
Johnson & Johnson's experimental drug, seltorexant, has shown promising results in a late-stage trial, improving depressive symptoms and sleep disturbances in patients with major depressive disorder (MDD). The drug, targeting orexin-2 receptors linked to the body's sleep-wake rhythm, met main and secondary trial goals. Around 60% of MDD patients on standard oral antidepressants experience residual insomnia symptoms, as noted by the company.
May 29, 2024
8 Articles